These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31392821)

  • 21. Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver.
    Carotti S; Lettieri-Barbato D; Piemonte F; Ruggiero S; Rosina M; Zalfa F; Zingariello M; Arciprete F; Valentini F; Francesconi M; D'Amico J; De Vincentis A; Baiocchini A; Perrone G; Antonelli-Incalzi R; Morini S; Picardi A; Aquilano K; Vespasiani-Gentilucci U
    Cell Death Dis; 2021 Nov; 12(12):1092. PubMed ID: 34795230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study.
    Hara M; Tanaka S; Torisu K; Matsukuma Y; Tsuchimoto A; Tokumoto M; Ooboshi H; Nakano T; Tsuruya K; Kitazono T
    Clin Exp Nephrol; 2021 Aug; 25(8):822-834. PubMed ID: 33856608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
    Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
    Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
    Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study.
    Rotundo L; Persaud A; Feurdean M; Ahlawat S; Kim HS
    Clin Mol Hepatol; 2018 Dec; 24(4):392-401. PubMed ID: 30068065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
    Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
    Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.
    Unger LW; Herac M; Staufer K; Salat A; Silberhumer G; Hofmann M; Trauner M; Rasoul-Rockenschaub S; Soliman T; Reiberger T; Berlakovich GA
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):309-316. PubMed ID: 27922486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct comparison of the specialised blood fibrosis tests FibroMeter
    Guillaume M; Moal V; Delabaudiere C; Zuberbuhler F; Robic MA; Lannes A; Metivier S; Oberti F; Gourdy P; Fouchard-Hubert I; Selves J; Michalak S; Peron JM; Cales P; Bureau C; Boursier J
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1214-1222. PubMed ID: 31617224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey.
    Hartleb M; Barański K; Zejda J; Chudek J; Więcek A
    Liver Int; 2017 Nov; 37(11):1706-1714. PubMed ID: 28489307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Serum Fibrosis Markers are Associated with Coronary Artery Calcification in Patients with Nonalcoholic Fatty Liver Disease.
    Song DS; Chang UI; Kang SG; Song SW; Yang JM
    Gut Liver; 2019 Nov; 13(6):658-668. PubMed ID: 30970434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study.
    Williams KH; Vieira De Ribeiro AJ; Prakoso E; Veillard AS; Shackel NA; Brooks B; Bu Y; Cavanagh E; Raleigh J; McLennan SV; McCaughan GW; Keane FM; Zekry A; Gorrell MD; Twigg SM
    J Diabetes; 2015 Nov; 7(6):809-19. PubMed ID: 25350950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.